Questcor Pharmaceuticals Hits New 12-Month High at $96.65 (QCOR)
Questcor Pharmaceuticals (NASDAQ:QCOR) shares reached a new 52-week high during mid-day trading on Monday , American Banking and Market News reports. The company traded as high as $96.65 and last traded at $96.42, with a volume of 1,738,319 shares trading hands. The stock had previously closed at $92.96.
QCOR has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 1st. They now have a $97.00 price target on the stock. Separately, analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Finally, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $86.20.
The stock’s 50-day moving average is $91.00 and its 200-day moving average is $75.22. The company has a market cap of $5.763 billion and a price-to-earnings ratio of 17.55. Questcor Pharmaceuticals also saw a significant decrease in short interest in June. As of June 30th, there was short interest totalling 17,989,114 shares, a decrease of 6.5% from the June 13th total of 19,245,387 shares. Based on an average daily volume of 2,017,510 shares, the short-interest ratio is presently 8.9 days. Approximately 30.2% of the shares of the stock are sold short.
Questcor Pharmaceuticals (NASDAQ:QCOR) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.40 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter last year, the company posted $0.76 earnings per share. Questcor Pharmaceuticals’s revenue was up 68.1% compared to the same quarter last year. Analysts expect that Questcor Pharmaceuticals will post $6.89 EPS for the current fiscal year.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.